Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Gemtuzumab-ozogamicin

Moore J, Seiter K, Kolitz J et al (2006) A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse. Leuk Res 30(7) 777-783... [Pg.188]

Gemtuzumab ozogamicin Humanized anti-CD33 antibody... [Pg.1408]

Bross, P.F., Beitz, J., Chen, G., Chen, X.H., Duffy, E., Kieffer, L., Roy, S., Sridhara, R., Rahman, A., Williams, G., and Pazdur, R. (2001) Approval summary Gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin. Cancer Res. 7, 1490-1496. [Pg.1051]

Gemtuzumab ozogamicin (Mylotarg M) Immunotoxin conjugate Second-line AML 60 years or older Phase II response... [Pg.447]

Bross, RE et al.. Approval Summary Gemtuzumab Ozogamicin in relapsed acute myeloid leukemia, Clin. Can. Res., 7,1490-1496, 2001. [Pg.458]

Gemtuzumab ozogamicin Mylotarg Humanized lgG4K anti-CD33 immunotoxin (calicheamicin) Relapsed acute myeloid leukemia 2000 United States... [Pg.114]

Gemtuzumab ozogamicin (30 Mylotarg ) Calicheamicin (31) Enediyne-type antibiotic NP-derived Microbial Anticancer DNA-cleaving 319-331... [Pg.19]

Giles F, Estey E, O Brien S. (2003) Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer 98 2095-2104. [Pg.140]

Giles FJ, Kantarjian HM, Komblau SM, Thomas DA, Garcia-Manero G Waddelow TA, David CL, Phan AT, Colburn DE, Rashid A, Estey EH. (2001) Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 92 406-413. [Pg.140]

Pagano L, Fianchi L, Caira M, Rutella S, Leone G. (2007) The role of gemtuzumab ozogamicin in the treatment of acute myeloid leukemia patients. [Pg.140]

Gemtuzumab Ozogamicin Acute myelogenous leukaemia (CD33)... [Pg.62]

CD3 (muromonab-CD3), CD20 (Ritux-imab), CD25 (Basiliximab Daclizumab), CD33- (Gemtuzumab-ozogamicin), CD52 (Alemtuzumab)... [Pg.32]

Mylotarg (Gemtuzumab ozogamicin) CD32 Humanized IgG4 Relapsed acute myeloid leukemia 2000... [Pg.278]

A. General description Gemtuzumab ozogamicin is composed of a recombinant humanized IgG4, kappa antibody conjugated with a cytotoxic antitumor antibiotic, calicheamicin. The anti-CD33 antibody is produced by mammalian cell suspension... [Pg.300]

Pharmacokinetics According to the product label, after administration of the first recommended dose of gemtuzumab ozogamicin, the elimination half-lives of total and unconjugated calicheamicin were about 45 and 100 hours, respectively. After the second dose, the half-life of total calicheamicin was increased to about 60 hours and the area under the curve (AUC) was about twice that following the first dose. The pharmacokinetics of unconjugated calicheamicin did not appear to change from dose one to dose two. [Pg.301]

Disposition Metabolic studies indicate hydrolytic release of the calicheamicin derivative from gemtuzumab ozogamicin. Many metabolites of this derivative were found after in vitro incubation of gemtuzumab ozogamicin in human liver microsomes and cytosol, and in HL-60 promyelocytic leukemia cells. Metabolic studies characterizing the possible isozymes involved in the metabolic pathway of Mylotarg have not been performed. [Pg.301]

G. Other considerations Gemtuzumab ozogamicin has been designated an orphan product for use in the treatment of CD33-positive AML. [Pg.302]

Gemtuzumab ozogamicin) [Mammalian-expressed recombinant humanized IgG4 conjugated with a cytotoxic antitumor antibiotic]... [Pg.320]

Gemtuzumab-ozogamicin is administered as a dose of 9mg/m2 and is infused over a 2-h period prior to its infusion, reduction of the leukocyte count in patients to below 30,000/ml is recommended. A second dose is administered after a 14-day interval. The elimination half-life of total calicheamicin is about 41 h after the first dose, 64 h after the second dose, and in its unconjugated form it is 143 h. The most common side effects associated with gemtuzumab-ozogamicin are fever and chills. [Pg.118]

Other adverse effects resulting from the administration of gemtuzumab-ozogamicin include myelosuppression, thrombocytopenia, neutropenia, increased risk of infection, abdominal pain, vomiting and headache. [Pg.119]

Lo-Coco F, Cimino G, Breccia M, Noguera NI, et al. 2004. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 104 1995-1999. [Pg.124]

See other pages where Gemtuzumab-ozogamicin is mentioned: [Pg.268]    [Pg.1294]    [Pg.1294]    [Pg.1410]    [Pg.589]    [Pg.591]    [Pg.39]    [Pg.39]    [Pg.39]    [Pg.140]    [Pg.620]    [Pg.67]    [Pg.177]    [Pg.301]    [Pg.301]    [Pg.555]    [Pg.204]    [Pg.1197]    [Pg.1197]    [Pg.177]    [Pg.118]    [Pg.118]   
See also in sourсe #XX -- [ Pg.1294 ]

See also in sourсe #XX -- [ Pg.39 ]

See also in sourсe #XX -- [ Pg.177 ]

See also in sourсe #XX -- [ Pg.300 , Pg.301 ]

See also in sourсe #XX -- [ Pg.177 ]

See also in sourсe #XX -- [ Pg.69 , Pg.73 , Pg.87 , Pg.313 , Pg.317 ]

See also in sourсe #XX -- [ Pg.47 ]

See also in sourсe #XX -- [ Pg.156 , Pg.178 ]

See also in sourсe #XX -- [ Pg.339 ]

See also in sourсe #XX -- [ Pg.295 ]

See also in sourсe #XX -- [ Pg.902 , Pg.903 , Pg.904 ]

See also in sourсe #XX -- [ Pg.177 ]

See also in sourсe #XX -- [ Pg.21 ]

See also in sourсe #XX -- [ Pg.353 ]



SEARCH



Gemtuzumab

© 2024 chempedia.info